Related Experiment Video
Updated: Jun 13, 2026
06:09
Using En Face Immunofluorescence Staining to Observe Vascular Endothelial Cells Directly
Published on: August 20, 2019
Soluble epoxide hydrolase in atherosclerosis.
Yi-Xin Jim Wang1, Arzu Ulu, Le-Ning Zhang
1Arete Therapeutics Inc., 7000 Shoreline Court, Suite 201, South San Francisco, CA 94080, USA. yxwang2000@gmail.com
Current Atherosclerosis Reports
|April 29, 2010
Summary
Soluble epoxide hydrolase inhibitors (sEHIs) show therapeutic potential for atherosclerosis by stabilizing beneficial epoxyeicosatrienoic acids (EETs). This approach reduces inflammation and improves cholesterol levels, offering a promising new cardiovascular disease treatment.
Area of Science:
- Biochemistry
- Pharmacology
- Cardiovascular Medicine
Background:
- Epoxyeicosatrienoic acids (EETs) are eicosanoids with beneficial effects on blood pressure, inflammation, and atherosclerosis.
- Soluble epoxide hydrolase (sEH) metabolizes EETs to less active diols, limiting their therapeutic potential.
- Genetic variations in the sEH (Ephx2) gene are linked to increased cardiovascular disease risk.
Purpose of the Study:
- To investigate the therapeutic potential of inhibiting sEH for treating atherosclerosis.
- To evaluate the antiatherosclerotic effects of sEH inhibitors (sEHIs) in preclinical models.
Main Methods:
- Administration of different sEHIs to apolipoprotein E-deficient mice.
- Assessment of atherosclerosis development and aneurysm formation.
- Analysis of EET levels, lipid profiles, and gene/protein expression.
Main Results:
- sEHIs significantly attenuated atherosclerosis and aneurysm formation in mice.
- Antiatherosclerotic effects correlated with increased EET levels.
- sEHI treatment led to reduced LDL, elevated HDL, and decreased expression of proinflammatory factors.
- Improved endothelial function and antihypertensive effects were also observed.
Conclusions:
- Inhibition of sEH is a promising therapeutic strategy for atherosclerosis.
- sEHIs offer a multi-faceted approach to cardiovascular disease treatment by modulating EET levels and inflammatory pathways.
- EETs and sEHIs represent a potential new class of therapeutics for atherosclerosis and related cardiovascular conditions.
Related Concept Videos
01:30Atherosclerosis I: Introduction
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:38Inflammation
Overview
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
02:57Sharpless Epoxidation
The conversion of allylic alcohols into epoxides using the chiral catalyst was discovered by K. Barry Sharpless and is known as Sharpless epoxidation. The use of a chiral catalyst enables the formation of one enantiomer of the product in excess. This chiral catalyst is mainly a chiral complex of titanium tetraisopropoxide and tartrate ester (specific stereoisomer). The stereoisomer used in the chiral catalyst dictates the formation of the enantiomer of the product. In other words, the use of...